Background A Fortune 500 company received a Warning Letter from the FDA citing findings of device adulteration and misbranding, along with potential regulatory actions including product seizure, injunction, and civil monetary penalties. The Warning Letter followed the FDA’s determination that the company’s responses to specific FDA 483 observations were inadequate. Regulatory Compliance Associates® Inc. (RCA) … Continue reading FDA 483 Warning Letter Remediation